Xiaoping Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoping Yang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Bin Yin
Department of Respiratory Diseases Qingdao Haici Hospital Affiliated to Qingdao University Qingdao China
1 shared publication- Bin Yin
Department of PCCM2, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, Shandong, China
1 shared publication - Chang-Lun Shao
Ocean University of China
1 shared publication Dongmei Wang
Department of Respiratory Diseases Qingdao Haici Hospital Affiliated to Qingdao University Qingdao China
1 shared publicationHuiying Liu
Qingdao Hospital of Traditional Chinese Medicine, Qingdao Haici Hospital, Qingdao, Shandong, China
1 shared publication- Huiying Liu
Qingdao Haici Hospital Affiliated to Qingdao University
1 shared publication
Latest Publications
- Open Access
- 8 August 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (8) , e70279
A Case of Advanced Lung Adenocarcinoma Successfully Treated by Intratumoral Injection of Tirelizumab Under Tracheoscopy
Introduction: Lung cancer is a leading cause of cancer‐related deaths, with an annual mortality rate of nearly 1.8 million. Among its subtypes, lung adenocarcinoma is increasingly prevalent. Due to its often asymptomatic nature, most patients are diagnosed at advanced stages, missing the optimal window for surgery and resulting in a poor 5‐year survival rate.Case Presentation: We present the case of an 83‐year‐old patient with stage IV lung adenocarcinoma treated with four cycles of intravenous Tirelizumab and two cycles of intratumoral Tirelizumab via tracheoscopy. The patient achieved partial clinical remission, with tumor lesions continuing to shrink upon follow‐up by August 24, 2024. No treatment‐related adverse reactions were observed, and the patient's immune function remained normal.Conclusions: This case suggests that systemic intravenous Tirelizumab combined with tracheoscopic intratumoral injection may offer a safe and effective treatment strategy for lung adenocarcinoma, particularly for patients unsuitable for chemotherapy or surgery. However, further prospective studies and clinical trials are needed to validate these findings.
- 8 August 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (8) , e70279
Open AccessA Case of Advanced Lung Adenocarcinoma Successfully Treated by Intratumoral Injection of Tirelizumab Under Tracheoscopy
Introduction: Lung cancer is a leading cause of cancer‐related deaths, with an annual mortality rate of nearly 1.8 million. Among its subtypes, lung adenocarcinoma is increasingly prevalent. Due to its often asymptomatic nature, most patients are diagnosed at advanced stages, missing the optimal window for surgery and resulting in a poor 5‐year survival rate.Case Presentation: We present the case of an 83‐year‐old patient with stage IV lung adenocarcinoma treated with four cycles of intravenous Tirelizumab and two cycles of intratumoral Tirelizumab via tracheoscopy. The patient achieved partial clinical remission, with tumor lesions continuing to shrink upon follow‐up by August 24, 2024. No treatment‐related adverse reactions were observed, and the patient's immune function remained normal.Conclusions: This case suggests that systemic intravenous Tirelizumab combined with tracheoscopic intratumoral injection may offer a safe and effective treatment strategy for lung adenocarcinoma, particularly for patients unsuitable for chemotherapy or surgery. However, further prospective studies and clinical trials are needed to validate these findings.
- Open Access
- 23 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (21) , e42536
Anti-MDA5 antibody positive dermatomyositis complicated by interstitial lung disease with an improved outcome: A case report
Rationale: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (MDA5-DM) is an autoimmune disease, characterized by a particular skin ulcer and rapidly progressive interstitial lung disease (RP-ILD). This case highlights diagnostic challenges of this disease and underscores the importance of early recognition and timely intervention. Patient concerns: A 59-year-old woman presented to the hospital with systemic myalgia, fatigue, and anorexia. Following admission she developed recurrent fever. Computed tomography of the chest and bronchoalveolar lavage fluid analysis revealed severe pulmonary infections. Despite 2 weeks of antimicrobial therapy yielding radiographic improvement, her dermatomyositis symptoms worsened. Diagnoses: Immune profiling and myositis-specific antibody testing confirmed the diagnosis of MDA5-DM-ILD. Interventions: The following treatment included methylprednisolone combined with immunosuppressants (tofacitinib, tacrolimus, tocilizumab, mycophenolate mofetil). Subsequent computed tomography imaging demonstrated cavity lesions and micronodules, with lung biopsy confirming fungal and viral coinfections. Therapy was adjusted to sustained methylprednisolone (22 mg/d), tacrolimus (0.5 g/d), targeted antimicrobials (ganciclovir, voriconazole) and prophylactic use of sulfamethoxazole complex. Outcomes: At discharge, the patient achieved clinical stability with resolved fever, normalized oxygen saturation and improved myalgia, though mild epigastric discomfort persisted. Lessons: MDA5-DM-ILD poses challenges for clinicians due to its diagnostic difficulty, rapid progression and secondary infection risks. Early immunosuppression combined with infection prevention is the key to a successful treatment of this disease.
- 23 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (21) , e42536
Open AccessAnti-MDA5 antibody positive dermatomyositis complicated by interstitial lung disease with an improved outcome: A case report
Rationale: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (MDA5-DM) is an autoimmune disease, characterized by a particular skin ulcer and rapidly progressive interstitial lung disease (RP-ILD). This case highlights diagnostic challenges of this disease and underscores the importance of early recognition and timely intervention. Patient concerns: A 59-year-old woman presented to the hospital with systemic myalgia, fatigue, and anorexia. Following admission she developed recurrent fever. Computed tomography of the chest and bronchoalveolar lavage fluid analysis revealed severe pulmonary infections. Despite 2 weeks of antimicrobial therapy yielding radiographic improvement, her dermatomyositis symptoms worsened. Diagnoses: Immune profiling and myositis-specific antibody testing confirmed the diagnosis of MDA5-DM-ILD. Interventions: The following treatment included methylprednisolone combined with immunosuppressants (tofacitinib, tacrolimus, tocilizumab, mycophenolate mofetil). Subsequent computed tomography imaging demonstrated cavity lesions and micronodules, with lung biopsy confirming fungal and viral coinfections. Therapy was adjusted to sustained methylprednisolone (22 mg/d), tacrolimus (0.5 g/d), targeted antimicrobials (ganciclovir, voriconazole) and prophylactic use of sulfamethoxazole complex. Outcomes: At discharge, the patient achieved clinical stability with resolved fever, normalized oxygen saturation and improved myalgia, though mild epigastric discomfort persisted. Lessons: MDA5-DM-ILD poses challenges for clinicians due to its diagnostic difficulty, rapid progression and secondary infection risks. Early immunosuppression combined with infection prevention is the key to a successful treatment of this disease.
- 21 April 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 292, 117670
Marine natural products as potential anti-Pseudomonas aeruginosa agents: challenges and advances
- 21 April 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 292, 117670
Marine natural products as potential anti-Pseudomonas aeruginosa agents: challenges and advances
- Open Access
- 9 October 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 14, 1476605
Host-dependent C-to-U RNA editing in SARS-CoV-2 creates novel viral genes with optimized expressibility
Rampant C-to-U RNA editing drives the mutation and evolution of SARS-CoV-2. While much attention has been paid to missense mutations, the C-to-U events leading to AUG and thus creating novel ORFs were uninvestigated. By utilizing the public time-course mutation data from the worldwide SARS-CoV-2 population, we systematically identified the “AUG-gain mutations” caused by C-to-U RNA editing. Synonymous mutations were of special focus. A total of 58 synonymous C-to-U sites are able to create out-of-frame AUG in coding sequence (CDS). These 58 synonymous sites showed significantly higher allele frequency (AF) and increasing rate (dAF/dt) than other C-to-U synonymous sites in the SARS-CoV-2 population, suggesting that these 58 AUG-gain events conferred additional benefits to the virus and are subjected to positive selection. The 58 predicted new ORFs created by AUG-gain events showed the following advantages compared to random expectation: they have longer lengths, higher codon adaptation index (CAI), higher Kozak scores, and higher tRNA adaptation index (tAI). The 58 putatively novel ORFs have high expressibility and are very likely to be functional, providing an explanation for the positive selection on the 58 AUG-gain mutations. Our study proposed a possible mechanism of the emergence of de novo genes in SARS-CoV-2. This idea should be helpful in studying the mutation and evolution of SARS-CoV-2.
- 9 October 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 14, 1476605
Open AccessHost-dependent C-to-U RNA editing in SARS-CoV-2 creates novel viral genes with optimized expressibility
Rampant C-to-U RNA editing drives the mutation and evolution of SARS-CoV-2. While much attention has been paid to missense mutations, the C-to-U events leading to AUG and thus creating novel ORFs were uninvestigated. By utilizing the public time-course mutation data from the worldwide SARS-CoV-2 population, we systematically identified the “AUG-gain mutations” caused by C-to-U RNA editing. Synonymous mutations were of special focus. A total of 58 synonymous C-to-U sites are able to create out-of-frame AUG in coding sequence (CDS). These 58 synonymous sites showed significantly higher allele frequency (AF) and increasing rate (dAF/dt) than other C-to-U synonymous sites in the SARS-CoV-2 population, suggesting that these 58 AUG-gain events conferred additional benefits to the virus and are subjected to positive selection. The 58 predicted new ORFs created by AUG-gain events showed the following advantages compared to random expectation: they have longer lengths, higher codon adaptation index (CAI), higher Kozak scores, and higher tRNA adaptation index (tAI). The 58 putatively novel ORFs have high expressibility and are very likely to be functional, providing an explanation for the positive selection on the 58 AUG-gain mutations. Our study proposed a possible mechanism of the emergence of de novo genes in SARS-CoV-2. This idea should be helpful in studying the mutation and evolution of SARS-CoV-2.